France France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition. With Brexit uncertainties across the channel and populist tendencies souring the prospects of some of its neighbours, France – under…
Korea Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology and rare diseases. She also documents Ipsen’s rapid local growth and increasing market share. Miss Kim also gives her assessment of the current drug pricing situation, as…
Ipsen Following on from Johnson & Johnson’s acquisition of Actelion in January 2017 and Takeda’s takeover of Shire two years later, pharma multinationals’ rush to snap up rare disease specialists continues with Ipsen’s proposed acquisition of Clementia Pharmaceuticals. Industry insiders predict that this trend is set to continue well into the…
China This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. We start in China, where the heads of Merck, Ipsen, Chiesi, Gedeon Richter and AbbVie’s Chinese affiliates give their…
Algeria Adlane Soudani, general manager of Ipsen’s Algerian affiliate, lifts the lid on Ipsen’s ambitions for the local market, and the company’s parallel strategies to ramp up local production while simultaneously delivering tech transfer to local partners. Our rather distinctive approach is to deploy parallel strategies: we will maintain our…
Algeria Ipsen’s Guillaume Freneuil gives his take on the importance of the Algerian market to the global group. If we are investing right now in Algeria it is because we envisage further growth here to be able to serve patient needs 33 percent of Sales within Ipsen are now in…
Spain Alfonso Beltrán García-Echániz, director of the Spanish Foundation for Innovation and Prospective Health (FIPSE), highlights the foundation’s focus, as a new instrument to foster innovation in Spain, as well as shares his expert insights on the future of innovation in the country. The focus of our work is to…
China Alan Chen, general manager for Ipsen China, shares the exciting journey of Ipsen in China in the past few years as the third-largest affiliate for the group globally, upcoming innovative product launches, the reorganization and HR strategy he has headed to take Ipsen China to the next stage of its…
Top 10 Geoffrey Guy, David Meek, Tae Han Kim, Pierre Moustial, Vivek Sharma, Antonio Portela and many other remarkable people that are shaping the global life sciences industry shared with PharmaBoardroom valuable insights on the companies they lead and their vision for the future. Geoffrey Guy Geoffrey Guy is the chairman and founder…
France Ipsen CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From our roots as a French company, we have blossomed into a growing international player within the areas of oncology, neuroscience and…
Algeria A sudden imposition of import restrictions on pharmaceuticals in 2017 has pushed several multinational companies to establish local production facilities in Algeria. However, the localization process can be fraught both for companies that establish direct manufacturing footprints via joint ventures and those that employ the services of local contract manufacturers.…
France Ipsen global CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From our roots as a French company, we have blossomed into a growing international player within the areas of oncology, neuroscience and…
See our Cookie Privacy Policy Here
